Su Jok therapy for chemo side effects
Part of Cancer, Pain clinical trials.
This study tests if Su Jok therapy (a gentle hand therapy) can help with pain, tiredness, nausea, vomiting, and emotional well-being for people getting chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with cancer
- You are currently receiving chemotherapy
- You are able to communicate clearly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a simple seed therapy called Su Jok (gentle seeds placed on the hand) can help reduce pain, anxiety, and improve emotional strength for people staying in the cancer ward.
This trial tests whether combining electroacupuncture with self-acupressure can improve quality of life for people with early-stage breast cancer during chemotherapy. The treatment is non-invasive and aims to reduce side effects.
This study tests a teaching session about managing chemotherapy symptoms and improving quality of life. It is designed to help you feel more in control of your treatment side effects.
This study tests if a traditional Chinese medicine hot pack can help reduce nerve pain caused by chemotherapy drugs like platinum and paclitaxel. It also looks at how to best care for patients during this treatment.
This trial tests if acupuncture can prevent nerve damage caused by certain chemotherapy drugs. It is for people with early-stage breast, stomach, colon, lung, or ovarian cancer who have not had nerve symptoms before.
This trial tests a new drug called JMKX000189 to see if it can safely reduce nerve pain and tingling caused by cancer chemotherapy. If you've completed cancer treatment and are struggling with these symptoms, this study may help.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.